https://orcid.org/0000-0002-4907-812X
References
- Amos TB, Tandon N, Lefebvre P, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a us commercial claims database. J Clin Psychiatry. 2018;79(2):24–32.
- Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA. 2003;289(23):3135–3144.
- Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161(15):1849–1856.
- van Dooren FE, Nefs G, Schram MT, et al. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One. 2013;8(3):e57058.
- Goldney RD, Phillips PJ, Fisher LJ, et al. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004;27(5):1066–1070.
- Malone KM, Haas GL, Sweeney JA, et al. Major depression and the risk of attempted suicide. J Affect Disord. 1995;34(3):173–185.
- Hiranyatheb T, Nakawiro D, Wongpakaran T, et al. The impact of residual symptoms on relapse and quality of life among Thai depressive patients. Neuropsychiatr Dis Treat. 2016;12:3175–3181.
- Nil R, Lutolf S, Seifritz E. Residual symptoms and functionality in depressed outpatients: a one-year observational study in Switzerland with escitalopram. J Affect Disord. 2016;197:245–250.
- Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psych Services. 2009;60(11):1439–1445.
- Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012;9(5–6):41–46.
- Fortney JC, Pyne JM, Edlund MJ, et al. Relationship between antidepressant medication possession and treatment response. Gen Hosp Psychiatry. 2010;32(4):377–379.
- Yan T, Greene M, Chang E, et al. Impact of atypical antipsychotics as adjunctive therapy on psychiatric cost and utilization in patients with major depressive disorder. Clinocecon Outcomes Res. 2020; 12: 81–89.
- Broder MS, Greene M, Yan T, et al. Medication adherence, health care utilization, and costs in patients with major depressive disorder initiating adjunctive antipsychotic treatment. Clin Therapeutics. 2019;41(2):221–232.
- Gaspar FW, Zaidel CS, Dewa CS. Rates and determinants of use of pharmacotherapy and psychotherapy by patients with major depressive disorder. Psych Services. 2019;70(4):262–270.
- Kessing LV. Severity of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Br J Psych. 2004;184(2):153–156.
- Huang SH, LePendu P, Iyer SV, et al. Toward personalizing treatment for depression: predicting diagnosis and severity. J Am Med Inform Assoc. 2014;21(6):1069–1075.
- Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry. 2010;67(12):1265–1273.
- Gum AM, Hirsch A, Dautovich ND, et al. Six-month utilization of psychotherapy by older adults with depressive symptoms. Community Ment Health J. 2014;50(7):759–764.
- Mohr DC, Hart SL, Howard I, et al. Barriers to psychotherapy among depressed and nondepressed primary care patients. Ann Behav Med. 2006;32(3):254–258.
- Brenes GA, Danhauer SC, Lyles MF, et al. Barriers to mental health treatment in rural older adults. Am J Geriatr Psychiatry. 2015;23(11):1172–1178.
- Solmi M, Miola A, Croatto G, et al. How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. Braz J Psychiatry. 2021;43(2):189–202.